Background Schizophrenia is highly expensive in calculable and incalculable costs.
Measures which impact the cost in the most severely affected are likely to produce the greatest cost reductions.
Studies regarding clozapine in the USA have demonstrated clear cost-effectiveness, despite the high prescription costs.
There are no prior UK studies.
Method We performed a cost-effectiveness analysis comparing the three years prior to commencing clozapine to the period following establishment of clozapine treatment (mean 36.4 months) for 26 patients with chronic schizophrenia or schizoaffective disorder.
Results There was a significant improvement in all clinical ratings applied (and a mean net saving of £3768 per annum).
The cost-effectiveness ofclozapine was double that of conventional neuroleptics (15.2 pre-33.0 post-clozapine, P<0.005).
Conclusions As a naturalistic study our data provide valuable information on the cost-effectiveness ofclozapine in the UK.
Our methodology could be applied in a community setting or in the study of another atypical neuroleptic.
Mots-clés Pascal : Clozapine, Neuroleptique, Psychotrope, Schizophrénie, Psychose, Efficacité traitement, Analyse coût efficacité, Economie santé, Royaume Uni, Europe, Homme
Mots-clés Pascal anglais : Clozapine, Neuroleptic, Psychotropic, Schizophrenia, Psychosis, Treatment efficiency, Cost efficiency analysis, Health economy, United Kingdom, Europe, Human
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 97-0445146
Code Inist : 002B02B03. Création : 03/02/1998.